Date post: | 21-Dec-2014 |
Category: |
Investor Relations |
Upload: | ymbiosciences |
View: | 77 times |
Download: | 1 times |
1 YM AGM Presentation | November 2012
YM BioSciences
AGM Presentation
November 2012
2 YM AGM Presentation | November 2012
YM BioSciences 2012 Annual General Meeting
A. Formal Business
1) Fix Number of Directors to be Elected
2) Election of Directors
David Allan, Thomas Allen, Kapil Dhingra, Mark Entwistle, Henry
Friesen, Nick Glover, Catherine Mackey, Nicole Onetto and Tryon
Williams
3) Appointment of Auditors
4) Further Business and Termination of the Meeting
B. Presentation from Management
3 YM AGM Presentation | November 2012
Safe Harbor
This presentation may contain forward-looking statements, which reflect the Company's current
expectation regarding future events. These forward-looking statements involve risks and uncertainties
that may cause actual results, events or developments to be materially different from any future results,
events or developments expressed or implied by such forward-looking statements. Such factors
include, but are not limited to, changing market conditions, the successful and timely completion of
clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing,
new product development, uncertainties related to the regulatory approval process or the ability to
obtain drug product in sufficient quantity or at standards acceptable to health regulatory authorities to
complete clinical trials or to meet commercial demand, and other risks detailed from time to time in the
Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing
forward-looking statements include but are not limited to the following: that our product candidates will
generate positive efficacy and safety data in future clinical trials, and that YM and its various partners
will complete their respective clinical trials within the timelines communicated. Except as required by
applicable securities laws, we undertake no obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise.
4 YM AGM Presentation | November 2012
Strategic Priorities for FY2012
1. Ensure optimization of the clinical and commercial potential of CYT387
• Myelofibrosis as proof-of-concept/path-to-market indication: PI/II – PIII transition
• Explore strategic partnering to potentially maximize value of the asset
• Initiate preclinical studies to explore anemia mechanism of action
2. Build a portfolio of products with clinical and commercial potential
• R&D collaborations
• YMBA Intellectual Property estate and small molecule libraries; JAK/kinase
screening project
• In-licensing and M&A opportunities
3. Minimize and rationalize resource expenditures
• Support ongoing development of nimotuzumab by sub-licencees
• Review clinical and commercial opportunity for CYT997
5 YM AGM Presentation | November 2012
CYT387: Our Promising Lead Asset
Significant Opportunity
• A potentially differentiated drug in the emerging JAK class
Strong Fundamentals
• Under-served initial disease with $B market potential
• Compelling clinical proof-of-concept data
Rapid Progress
• 2.5 years of expanding clinical development
• Transitioning to Phase III
• Oriented towards commercialization
6 YM AGM Presentation | November 2012
Our Significant Expertise in JAK Research
YM acquired original intellectual assets in
JAK field
– Identified by Dr. Andrew Wilks, Ludwig
Cancer Institute, Melbourne, Founder of
Cytopia (now YM Australia)
– First group to publish crystal structures
of JAK2 and JAK1
– Medicinal chemistry and molecular
modeling expertise
Intellectual Property
CYT387 Composition of Matter
US: Pending, 2028 expiry
EU: Pending, 2028 expiry
JAK2 Crystal Structure
US: Issued, 2025 expiry
EU: Pending, 2026 expiry
JAK2 Enzyme
US: Issued, 2015 expiry
7 YM AGM Presentation | November 2012
Target Markets for JAK Inhibitors
Cancer /
Hematology Autoimmune
Diseases
– Rheumatoid
Arthritis
– Psoriasis
– Graft vs. Host
Disease
Myeloproliferative
Neoplasms
– Myelofibrosis
– Polycythemia Vera
– Essential
Thrombocythemia
– Leukemia and
Lymphoma
– Solid Tumors
– Other Hematologic
Disorders
Chronic Disorders Clinical Proof of Concept Acute Diseases
8 YM AGM Presentation | November 2012
Clinical Presentations of Myelofibrosis
A chronic debilitating disease in which a
patient’s bone marrow is replaced by scar
tissue
– Anemia – often requiring transfusions
– Thrombocytopenia
– Splenomegaly
– Constitutional symptoms
Fatigue, night sweats, pruritus, bone pain,
weight loss, fever
9 YM AGM Presentation | November 2012
Anemia Impacts Survival in Myelofibrosis
– ~70% of myelofibrosis patients are Intermediate-II or High risk †
– Estimated that 30-50% of all myelofibrosis patient are transfusion dependent‡,
majority of which are Intermediate-II and High risk patients
† DIPSS-Plus; Gangat et al. JCO 2011; 29(4), 392 ‡ Elena et al. Haematologica 2011 96(1) 167
Anemia at any time Anemia at diagnosis
10 YM AGM Presentation | November 2012
Transfusion Independence Response (as at ASH 2011)
1 Includes 100 mg QD (n=3), 200 mg QD (n=3), and 400 mg QD (n=6) doses 2 Not statistically significant vs. 300 mg QD
* Ongoing
Response by Dose 150 mg QD
(n=52)
300 mg QD
(n=60)
150 mg BID
(n=42)
Total1
(n=166)
Transfusion dependent at baseline (evaluable; n) 25 26 14 68
Median time on study (days) 251 245 141 250
Transfusion independence rate (12 weeks)* 48% 65% 43%2 54%
Transfusion independence rate (12 weeks & Hgb≥8g/dL)* 40% 62% 29%2 46%
– >25% of subjects not receiving transfusions while on study experienced at least a 1 g/dL increase in Hgb
for ≥ 8 weeks
Time to Response Median Min-Max
Time to confirmed response (12 wks & Hgb≥8 g/dL) (days) 84 84-293
Duration of transfusion-free period (12 wks & Hgb≥8 g/dL) (days) not yet reached 82-506*
11 YM AGM Presentation | November 2012
Maximum Duration of Transfusion-Free Period (as at ASH 2011, ongoing)
0 100 200 300 400 500
Time (days)
Re
sp
on
de
rs
* As at ASH 2011
Clinically relevant maintenance of
transfusion independence period
12 YM AGM Presentation | November 2012
Spleen Response (as at ASH 2011)
1 Includes 100 mg QD (n=3), 200 mg QD (n=3), and 400 mg QD (n=6) doses
* Ongoing
Response by Dose 150 mg QD
(n=52)
300 mg QD
(n=60)
150 mg BID
(n=42)
Total1
(n=166)
Spleen evaluable (n) 47 51 33 142
Median time on study* (days) 252 225 144 225
Spleen response* (IWG-MRT) 30% 33% 27% 31%
≥50% decrease in palpable spleen length at six months 28% 33% 39% 33%
Median spleen decrease at six months -35% -35% -39% -35%
Time to Response Median Min-Max
Time to IWG-MRT response (days) 15 6-260
Duration of response (days) not yet reached 55-574*
Response by Diagnosis Primary MF
(n=106)
Post-PV MF
(n=36)
Post-ET MF
(n=24)
Spleen evaluable (n) 88 34 20
Spleen response* (IWG-MRT) 28% 38% 30%
13 YM AGM Presentation | November 2012
Maximal Change in Palpable Spleen Size (as at ASH 2011, ongoing)
* Ongoing
-100%
-80%
-60%
-40%
-20%
0%
20%
40%
60%
80%
% C
han
ge F
rom
Baselin
e
(Core Study; n=142)
≥ 25% decrease from baseline: 87%
≥ 50% decrease from baseline: 49%
≥ 75% decrease from baseline: 25%
100% decrease from baseline: 16%
14 YM AGM Presentation | November 2012
Constitutional Symptoms Response at Six Months (as at ASH 2011)
23% 22% 23% 19%
11%
57% 52%
44%
30%
89%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Night Sweats(n=62)
Pruritis(n=46)
Bone Pain(n=43)
Cough(n=27)
Fever(n=9)
Perc
en
tag
e o
f P
ati
en
ts
Complete Resolution
Marked Improvement
Complete resolution or marked improvement of common constitutional
symptoms is achieved in the majority of subjects
15 YM AGM Presentation | November 2012
CYT387 – Safe, Effective, Differentiated
CYT387 treatment results in significant, durable responses in anemia,
splenomegaly and constitutional symptoms at all doses evaluated.
– Therapeutic benefit and safety established in a population with multiple risk
factors, including anemia and thrombocytopenia
– CYT387 anemia benefit appears unique among the current class of JAK1 and
JAK2 inhibitors
– Clinically relevant maintenance of transfusion independence period
– MRI performed in a subset of subjects confirms the meaningful improvement in
splenomegaly measured by palpation
– Complete resolution or marked improvement of common constitutional
symptoms is achieved in the majority of subjects
16 YM AGM Presentation | November 2012
Variable Diagnosis* >1 year* CYT387
Anemia 38% 64% Benefit
Transfusion dependency 25% 45% Benefit
Palpable spleen >10cm 21% 46% Benefit
Constitutional symptoms 29% 34% Benefit
CYT387: Meets Clinical Needs in Myelofibrosis
CYT387 has a profile that addresses MF clinical needs and overarching risk factors
> Benefit on anemia and transfusion dependency
> Activity for spleen and symptoms
> Low myelosuppression
CYT387 is well tolerated for dosing periods up to and exceeding two years
* Mayo Clin Proc 2012;87(1): 25-33
17 YM AGM Presentation | November 2012
Preclinical Preparation Activities
CYT387 Myelofibrosis Development Pathway
Feb 2010
Acquired
Cytopia
March 2010
Increased
CYT387 trial
from 21 to
60 patients
Aug 2010
CYT387
designated
Orphan
Drug
Nov 2010
Increased trial
from 60 to 140
patients and
added BID
cohort
Dec 2010
Reported
Interim 60
patient data
at ASH
July 2011
Reported
Interim 60
patient 12-week
data at ASCO
Sept 2011
Completed
enrollment of
166 patient trial
&
Initiated BID trial
Dec 2011
Reported Interim
166 patient
multicenter data
at ASH
June 2012
Completed
dosing of 166
patient trial
July 2012
Completed
enrollment
of 61
patient
BID trial
Dec 2012
Report Final 9-
month 166
patient data at
ASH
Partnering Campaign
PIII & Commercial Readiness
FDA and EMA Discussions
Capsules to tablet transition
Financing
Build Management
Expand Clinical Development
18 YM AGM Presentation | November 2012
CYT387: Next Steps
ASH 2012
• Podium presentation at ASH 2012
• Phase I/II Core study results reinforce differentiated profile
Business Development
• Exploring opportunities to develop CYT387 with other companies
• Conducted a broad, robust business development process
• Actively exploring variety of options
Phase III
• Preparations for Phase III ongoing
• Flexibility to advance CYT387 with or without a partner
19 YM AGM Presentation | November 2012